Pluristem Therapeutics Inc. (PSTI)

4.14
NASDAQ : Health Technology
Prev Close 4.24
Day Low/High 4.14 / 4.30
52 Wk Low/High 3.24 / 13.50
Avg Volume 273.00K
Exchange NASDAQ
Shares Outstanding 15.55M
Market Cap 65.85M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Pluristem Receives Regulatory Approval To Extend Its Phase II Study Of PLX-PAD Cells In The Treatment Of Intermittent Claudication To South Korea

Pluristem Receives Regulatory Approval To Extend Its Phase II Study Of PLX-PAD Cells In The Treatment Of Intermittent Claudication To South Korea

CHA Bio Will Conduct and Fund the Trial; PLX-PAD Cells Are the First Placental-Derived Allogeneic Cells Approved for Importation Into South Korea

Safety Of Pluristem's PLX Cells Demonstrated In Pre-Clinical Pregnancy Model

Safety Of Pluristem's PLX Cells Demonstrated In Pre-Clinical Pregnancy Model

Important Milestone Advances Pluristem's Clinical Development Program for the Treatment of Preeclampsia Using PLX-PAD Cells

Pluristem Receives Israeli Ministry Of Health Approval To Expand Its Phase II Clinical Trial In Intermittent Claudication To Israel

Pluristem Receives Israeli Ministry Of Health Approval To Expand Its Phase II Clinical Trial In Intermittent Claudication To Israel

International Study Extends FDA Phase II Trial That Began in U.S.

Pluristem Granted Key U.S. Patent For The Treatment Of Peripheral Artery Disease

Pluristem Granted Key U.S. Patent For The Treatment Of Peripheral Artery Disease

Exclusive Rights to Treat PAD With Placental Cells in the U.S.

Tendon Injuries Treated With Pluristem's PLX Cells Demonstrate Favorable Properties

Tendon Injuries Treated With Pluristem's PLX Cells Demonstrate Favorable Properties

Pre-Clinical Studies Conducted at New York's Hospital for Special Surgery

Pluristem Awarded A $3.3 Million Grant By Israeli Government

Pluristem Awarded A $3.3 Million Grant By Israeli Government

Supports Expanding Product Portfolio in Both Clinical Trials and Pre-Clinical R&D

Pluristem Completes Enrollment For Phase I/II Muscle Injury Trial

Pluristem Completes Enrollment For Phase I/II Muscle Injury Trial

Study Conducted in Germany Marks the First Time PLX-PAD Cells are Used for the Treatment of Surgically Induced Muscle Trauma

Pluristem Enters Into Strategic Partnership And Licensing Agreement With Cha Bio&Diostech For The Development And Commercialization Of PLX Cells For The Treatment Of CLI And IC In South Korea

Pluristem Enters Into Strategic Partnership And Licensing Agreement With Cha Bio&Diostech For The Development And Commercialization Of PLX Cells For The Treatment Of CLI And IC In South Korea

Cha Will Conduct and Fund Multiple Peripheral Artery Disease Clinical Trials and Invest $10 Million Valued at $4/Share Into Pluristem Via a Share Exchange Agreement

Pluristem's Preclinical Results For Its PLX-RAD Cells Published In The Journal PLOS ONE

Pluristem's Preclinical Results For Its PLX-RAD Cells Published In The Journal PLOS ONE

Pluristem's Cells Were Reported to Serve as Highly Effective "Off the Shelf" Therapy to Treat Acute Radiation Syndrome and Radiation Induced Bone Marrow Failure in Animals

Pluristem To Present At FDA Symposium

Pluristem To Present At FDA Symposium

Preclinical Research Shows PLX Cells May Be Effective In Treating Preeclampsia

Preclinical Research Shows PLX Cells May Be Effective In Treating Preeclampsia

No Treatment Exists Today for the Most Common Medical Complication of Pregnancy

Pluristem Develops PLX-RAD Cells For Use In Hematology

Pluristem Develops PLX-RAD Cells For Use In Hematology

Enhancing Hematopoietic Stem Cell Engraftment Will be the First Indication

Pluristem Expands PLX Product Portfolio In Orthopedics And Sports Medicine

Pluristem Expands PLX Product Portfolio In Orthopedics And Sports Medicine

Pluristem Plans to Initiate a Phase I Trial in Rotator Cuff Injuries

Pluristem Reports On The Progress Of Its Phase I/II Clinical Trial For The Treatment Of Muscle Injury

Pluristem Reports On The Progress Of Its Phase I/II Clinical Trial For The Treatment Of Muscle Injury

First Time Surgically Induced Muscle Injury Treated With PLX Cells

United Therapeutics Moves Forward Towards A Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension

United Therapeutics Moves Forward Towards A Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension

PLX Cells to be Administered Intravenously to Humans for the First Time, Opening Potential New Fields of Applications

TheStreet Quant Rating: D- (Sell)